Therefore, delivery of alloHCT in first complete remission (CR1) appears inappropriate for patients who can experience a long-term survival such as those with CBF-AML, biallelic CEBPA-mutated and NPM1-mutated AML. The gene discussed is CEBPA; the disease is acute myeloid leukemia.